Sanofi Drug Pipeline

Sanofi maintains a substantial clinical portfolio, with 1106 trials registered since 2008 and 131 currently active. These active programs span a range of development phases, including 22 in Phase 1, 56 in Phase 2, 57 in Phase 3, and 13 in Phase 4. Sanofi’s research activity extends across 16 therapeutic areas, with a notable concentration in Oncology, which accounts for 8% of active programs. Within Oncology, Multiple Myeloma represents the largest focus, with 8 active trials, 3 of which are in Phase 3. Other key therapeutic areas include Immunology, Respiratory, and Rare Diseases, each with 9 or more active trials, as well as Metabolic and Infectious Diseases. The Phase 3 weighting suggests a pipeline with a number of near-term potential catalysts. Beyond Multiple Myeloma, other oncology indications being actively investigated include Solid Tumor (Advanced), Non-Hodgkin Lymphoma, and NSCLC.